Alzheimer's stage what can you do ?

Alzheimer's disease treatments represent worldwide huge challengers and are among the most important nowadays concerns. New results, candidate therapeutics, and methodological issues will be some of the major worldwide issues discussed at the 2019 CTAD Congress. Alzheimer's disease symptoms and dementia treatment will be dealt with at the CTAD 2019 Congress. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. Safe drugs represent some of the future treatment trials in order to avoid Alzheimer's disease progression. The AD disease process can be minored thanks to non-pharmaceutical trials and that anti-amyloid treatment, as discussed at the 2018 CTAD Congress. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Studies on the early stage symptoms will be presented at the 2019 CTAD Congress by the clinical teams. The CTAD 2019 Congress will highlight the latest on trying to get these trials off the ground. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. Reviews, original research articles and short reports on Alzheimer prevention will be published in the JPAD . They will include articles on the following topics : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.